Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry
Lancet Respir Med
.
2018 Jul;6(7):495-496.
doi: 10.1016/S2213-2600(18)30192-9.
Epub 2018 May 4.
Authors
Diana Bilton
1
,
Noreen Caine
2
,
Steve Cunningham
3
,
Nicholas J Simmonds
4
,
Rebecca Cosgriff
2
,
Siobhán B Carr
5
Affiliations
1
Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK. Electronic address:
[email protected]
.
2
UK Cystic Fibrosis Trust, London, UK.
3
MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
4
Adult Cystic Fibrosis Centre, Royal Brompton and Harefield NHS Foundation Trust, London, UK; NHLI Imperial College, London, UK.
5
Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
PMID:
29735358
DOI:
10.1016/S2213-2600(18)30192-9
No abstract available
Publication types
Review
MeSH terms
Cooperative Behavior*
Drug Industry*
Humans
Product Surveillance, Postmarketing / methods*
Rare Diseases*
Registries*
United Kingdom